PitchBook-2025年二季度医疗技术公共报表和估值指南（英）-2025
EMERGING TECH RESEARCH PitchBook Data, Inc. Nizar Tarhuni Executive Vice President of Research
报告摘要
EMERGING TECH RESEARCH PitchBook Data, Inc. Nizar Tarhuni Executive Vice President of Research
核心要点
- 1 week
- 30 days
- 90 days
报告信息
- 文件全名
- 《PitchBook-2025年二季度医疗技术公共报表和估值指南（英）-2025-7页.pdf》
- 适合读者
- 核心数据
- all medtech subsectors posting median double-digit share price gains or higher—compared with a 9.7% gain for the S&P 500.
- Leading the pack were Tempus AI and Exact Sciences, with share price increases of 58% and 57%, respectively, as investors
- flocked to higher-risk, higher-reward diagnostic companies. Tempus shares have now climbed nearly 50% since the firm’s IPO
- in June 2024. Another company benefiting from renewed investor interest in liquid biopsy is Grail, with gains of 150% since its
- 核心议题
常见问题
《PitchBook-2025年二季度医疗技术公共报表和估值指南（英）-2025》主要包含哪些内容?
EMERGING TECH RESEARCH PitchBook Data, Inc. Nizar Tarhuni Executive Vice President of Research核心数据:all medtech subsectors posting median double-digit share price gains or higher—compared with a 9.7% gain for the S&P 500.;Leading the pack were Tempus AI and Exact Sciences, with share price increases of 58% and 57%, respectively, as investors;flocked to higher-risk, higher-reward diagnostic companies. Tempus shares have now climbed nearly 50% since the firm’s IPO。
这份报告由哪家机构发布?
本报告由PitchBook发布,发布于 2025 年。
这份报告覆盖哪一年、篇幅多大?
覆盖 2025 年,全文共 7 页。
这份报告是免费的吗?如何获取?
本报告免费查阅,登录资料宝后即可在线获取完整内容。
这份报告适合哪些读者?
适合战略规划、行业研究员等读者参考。
报告涉及哪些关键议题?
重点分析了医疗等议题。
继续阅读
查看全部 →